

Datasheet for ABIN6266125

**anti-ZNF337 antibody**

## 2 Images

[Go to Product page](#)

## Overview

Quantity:	100 µL
Target:	ZNF337
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This ZNF337 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

## Product Details

Immunogen:	A synthesized peptide derived from human ZNF337
Isotype:	IgG
Specificity:	ZNF337 Antibody detects endogenous levels of ZNF337
Cross-Reactivity:	Human
Purification:	The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).

## Target Details

Target:	ZNF337
Alternative Name:	ZNF337 ( <a href="#">ZNF337 Products</a> )
Background:	Description: May be involved in transcriptional regulation.

## Target Details


	Gene: ZNF337
Molecular Weight:	86kDa
Gene ID:	26152
UniProt:	<a href="#">Q9Y3M9</a>

## Application Details

Application Notes:	WB 1:500-1:2000, IF/ICC 1:100-1:500
Restrictions:	For Research Use only


## Handling

Format:	Liquid
Concentration:	1 mg/mL
Buffer:	Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store at -20 °C.Stable for 12 months from date of receipt
Expiry Date:	12 months



### Immunofluorescence (fixed cells)

**Image 1.** ABIN6266874 staining HeLa by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100, then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody.



### Western Blotting

**Image 2.** Western blot analysis on HeLa cell lysate using ZNF337 Antibody, The lane on the left is treated with the antigen-specific peptide.